A study to determine the safety and efficacy at different doses of EP-101 in subjects with moderate to Severe COPD.
- Registry ID
- EUCTR2011-001810-32
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Elevation Pharmaceuticals, Inc
- Start date
- 2011-06-02
- Completion date
- 2011-12-19
- Last update
- 2026-08-16
Conditions
- Chronic Obstructive Pulmonary Disease (COPD).
Summary
To determine the steady-state efficacy and dose-response profile of EP-101 administered once-daily via eFlow® nebulizer following 7 days of treatment in subjects with moderate to severe COPD.
Locations
View on source registry